Gilead's Tecartus gets conditional authorization in Europe for blood cancer

 

• The European Commission has granted conditional marketing authorization Kite's Tecartus (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Kite is a Gilead (NASDAQ:GILD) company.
• Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy.
• Conditional marketing authorization in Europe is initially valid for one year but can be extended or converted into an unconditional authorization after the submission and assessment of additional confirmatory data.
• https://seekingalpha.com/news/3644760-gileads-tecartus-receives-conditional-authorization-in-europe-for-blood-cancer